Diagnostic accuracy of methods for the detection of BRCA1 and BRCA2 mutations: a systematic review

Gerhardus A, Schleberger H, Schlegelberger B, Gadzicki D (2007)
EUROPEAN JOURNAL OF HUMAN GENETICS 15(6): 619-627.

Download
No fulltext has been uploaded. References only!
Journal Article | Review | Published | English

No fulltext has been uploaded

Author
; ; ;
Abstract / Notes
As sequence analysis for BRCA1 and BRCA2 mutations is both time- and cost-intensive, current strategies often include scanning techniques to identify fragments containing genetic sequence alterations. However, a systematic assessment of the diagnostic accuracy has been lacking so far. Here, we report on a systematic review to assess the internal and external validity of current scanning techniques. Inclusion criteria were: controlled design, investigators blinded, and tests suitable as a scanning tool for the whole genes BRCA1 and BRCA2. Outcome parameters were sensitivity, specificity, and positive and negative predictive values compared to direct sequencing. Out of 3816 publications, 10 studies reporting on 12 methods met our inclusion criteria. The internal and external validity of most of these studies was limited. Sensitivities were reported to be 100% for enzymatic mutation detection (EMD), multiple-dye cleavase fragment length polymorphism (MD-CFLP), fluorescence-based conformation-sensitive gel electrophoresis (F-CSGE), RNA-based sequencing, restriction endonuclease fingerprinting-single strand conformation polymorphism (REF-SSCP), stop codon (SC) assay, and denaturing high-performance liquid chromatography (DHPLC). Sensitivity was 50-96% for SSCP, 88-91% for two-dimensional gene scanning (TDGS), 76% for conformation-sensitive gel electrophoresis (CSGE), 75% for protein truncation test (PTT), and 58% for micronucleus test (MNT). Specificities close to 100% were reported, except for MNT. PTT and SC assay are only able to detect truncating mutations. Most studies were designed to introduce new experimental approaches or modifications of established methods and require further evaluation. F-CSGE, REF-SSCP, RNA-based sequencing, EMD, and MD-CFLP will need further evaluation before their use in a routine setting can be considered. SSCP, MNT, PTT, CSGE, and TDGS cannot be recommended because of their low sensitivity. DHPLC outperforms all other methods studied. However, none of the four studies evaluating DHPLC was performed on BRCA2.
Publishing Year
ISSN
eISSN
PUB-ID

Cite this

Gerhardus A, Schleberger H, Schlegelberger B, Gadzicki D. Diagnostic accuracy of methods for the detection of BRCA1 and BRCA2 mutations: a systematic review. EUROPEAN JOURNAL OF HUMAN GENETICS. 2007;15(6):619-627.
Gerhardus, A., Schleberger, H., Schlegelberger, B., & Gadzicki, D. (2007). Diagnostic accuracy of methods for the detection of BRCA1 and BRCA2 mutations: a systematic review. EUROPEAN JOURNAL OF HUMAN GENETICS, 15(6), 619-627. doi:10.1038/sj.ejhg.5201806
Gerhardus, A., Schleberger, H., Schlegelberger, B., and Gadzicki, D. (2007). Diagnostic accuracy of methods for the detection of BRCA1 and BRCA2 mutations: a systematic review. EUROPEAN JOURNAL OF HUMAN GENETICS 15, 619-627.
Gerhardus, A., et al., 2007. Diagnostic accuracy of methods for the detection of BRCA1 and BRCA2 mutations: a systematic review. EUROPEAN JOURNAL OF HUMAN GENETICS, 15(6), p 619-627.
A. Gerhardus, et al., “Diagnostic accuracy of methods for the detection of BRCA1 and BRCA2 mutations: a systematic review”, EUROPEAN JOURNAL OF HUMAN GENETICS, vol. 15, 2007, pp. 619-627.
Gerhardus, A., Schleberger, H., Schlegelberger, B., Gadzicki, D.: Diagnostic accuracy of methods for the detection of BRCA1 and BRCA2 mutations: a systematic review. EUROPEAN JOURNAL OF HUMAN GENETICS. 15, 619-627 (2007).
Gerhardus, Ansgar, Schleberger, Henriette, Schlegelberger, Brigitte, and Gadzicki, Dorothea. “Diagnostic accuracy of methods for the detection of BRCA1 and BRCA2 mutations: a systematic review”. EUROPEAN JOURNAL OF HUMAN GENETICS 15.6 (2007): 619-627.
This data publication is cited in the following publications:
This publication cites the following data publications:

40 Citations in Europe PMC

Data provided by Europe PubMed Central.

CFTR transcription defects in pancreatic sufficient cystic fibrosis patients with only one mutation in the coding region of CFTR.
Sheridan MB, Hefferon TW, Wang N, Merlo C, Milla C, Borowitz D, Green ED, Mogayzel PJ, Cutting GR., J Med Genet 48(4), 2011
PMID: 21097845
Advantage of high-resolution melting curve analysis over conformation-sensitive gel electrophoresis for mutational screening of BRCA1 and BRCA2 genes.
de Juan Jiménez I, Cardeñosa EE, Suela SP, González EB, Trejo DS, Lluch OF, Gilabert PB., Clin Chim Acta 412(7-8), 2011
PMID: 21147080
Massive parallel amplicon sequencing of the breast cancer genes BRCA1 and BRCA2: opportunities, challenges, and limitations.
De Leeneer K, Hellemans J, De Schrijver J, Baetens M, Poppe B, Van Criekinge W, De Paepe A, Coucke P, Claes K., Hum Mutat 32(3), 2011
PMID: 21305653
BRCA1 deficient mouse models to study pathogenesis and therapy of triple negative breast cancer.
Diaz-Cruz ES, Cabrera MC, Nakles R, Rutstein BH, Furth PA., Breast Dis 32(1-2), 2010
PMID: 21778574
A one-step prescreening for point mutations and large rearrangement in BRCA1 and BRCA2 genes using quantitative polymerase chain reaction and high-resolution melting curve analysis.
Coulet F, Pires F, Rouleau E, Lefol C, Martin S, Colas C, Cohen-Haguenauer O, Giurgea I, Fajac A, Noguès C, Demange L, Hardouin A, Lidereau R, Soubrier F., Genet Test Mol Biomarkers 14(5), 2010
PMID: 20858050
An ELISA-based high throughput protein truncation test for inherited breast cancer.
Lim MJ, Foster GJ, Gite S, Ostendorff HP, Narod S, Rothschild KJ., Breast Cancer Res 12(5), 2010
PMID: 20920338
Diagnostic guidelines for high-resolution melting curve (HRM) analysis: an interlaboratory validation of BRCA1 mutation scanning using the 96-well LightScanner.
van der Stoep N, van Paridon CD, Janssens T, Krenkova P, Stambergova A, Macek M, Matthijs G, Bakker E., Hum Mutat 30(6), 2009
PMID: 19370767
c.1810C>T polymorphism of NTRK1 gene is associated with reduced survival in neuroblastoma patients.
Lipska BS, Drozynska E, Scaruffi P, Tonini GP, Izycka-Swieszewska E, Zietkiewicz S, Balcerska A, Perek D, Chybicka A, Biernat W, Limon J., BMC Cancer 9(), 2009
PMID: 20003389
Mutation detection using ENDO1: application to disease diagnostics in humans and TILLING and Eco-TILLING in plants.
Triques K, Piednoir E, Dalmais M, Schmidt J, Le Signor C, Sharkey M, Caboche M, Sturbois B, Bendahmane A., BMC Mol Biol 9(), 2008
PMID: 18433472
Mutation screening of the BRCA1 gene in sporadic breast cancer in southern Chinese populations.
Haitian Z, Yunfei L, Jian Z, Jian L, Qinghua L, Fuqiang W., Breast 17(6), 2008
PMID: 18835712
"Sequencing-grade" screening for BRCA1 variants by oligo-arrays.
Monaco A, Menolascina F, Zhao Y, Tommasi S, Sabatino M, Fasano R, Paradiso A, Marincola FM, Wang E., J Transl Med 6(), 2008
PMID: 18973698
Genetic counselling and testing for inherited gene mutations in newly diagnosed patients with breast cancer: a review of the existing literature and a proposed research agenda.
Meiser B, Tucker K, Friedlander M, Barlow-Stewart K, Lobb E, Saunders C, Mitchell G., Breast Cancer Res 10(6), 2008
PMID: 19090970

39 References

Data provided by Europe PubMed Central.

Detection of germline BRCA1 mutations by Multiple-Dye Cleavase Fragment Length Polymorphism (MD-CFLP) method.
Casadei S, Cortesi L, Pensotti V, Radice P, Pierotti M, Amadori D, Calistri D., Br. J. Cancer 85(6), 2001
PMID: 11556835
BRCA1 mutation screening using restriction endonuclease fingerprinting-single-strand conformation polymorphism in an automated capillary electrophoresis system.
Kringen P, Egedal S, Pedersen JC, Harbitz TB, Tveit KM, Berg K, Borresen-Dale AL, Andersen TI., Electrophoresis 23(24), 2002
PMID: 12481264
A comparison of BRCA1 mutation analysis by direct sequencing, SSCP and DHPLC.
Gross E, Arnold N, Goette J, Schwarz-Boeger U, Kiechle M., Hum. Genet. 105(1-2), 1999
PMID: 10480358
Evaluation of the diagnostic accuracy of the stop codon (SC) assay for identifying protein-truncating mutations in the BRCA1and BRCA2genes in familial breast cancer.
Sakayori M, Kawahara M, Shiraishi K, Nomizu T, Shimada A, Kudo T, Abe R, Ohuchi N, Takenoshita S, Kanamaru R, Ishioka C., J. Hum. Genet. 48(3), 2003
PMID: 12624724

AUTHOR UNKNOWN, 0
Empirical evidence of design-related bias in studies of diagnostic tests.
Lijmer JG, Mol BW, Heisterkamp S, Bonsel GJ, Prins MH, van der Meulen JH, Bossuyt PM., JAMA 282(11), 1999
PMID: 10493205
Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer.
Lewis AG, Flanagan J, Marsh A, Pupo GM, Mann G, Spurdle AB, Lindeman GJ, Visvader JE, Brown MA, Chenevix-Trench G; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer., Breast Cancer Res. 7(6), 2005
PMID: 16280053
German populations with infrequent CHEK2*1100delC and minor associations with early-onset and familial breast cancer.
Rashid MU, Jakubowska A, Justenhoven C, Harth V, Pesch B, Baisch C, Pierl CB, Bruning T, Ko Y, Benner A, Wichmann HE, Brauch H, Hamann U; GENICA Network., Eur. J. Cancer 41(18), 2005
PMID: 16239104
The 471delAAAG mutation and C353T polymorphism in the RNASEL gene in sporadic and inherited cancer in Israel.
Dagan E, Laitman Y, Levanon N, Feuer A, Sidi AA, Baniel J, Korach Y, Ben Baruch G, Friedman E, Gershoni-Baruch R., Fam. Cancer 5(4), 2006
PMID: 16944274
Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method.
Hogervorst FB, Nederlof PM, Gille JJ, McElgunn CJ, Grippeling M, Pruntel R, Regnerus R, van Welsem T, van Spaendonk R, Menko FH, Kluijt I, Dommering C, Verhoef S, Schouten JP, van't Veer LJ, Pals G., Cancer Res. 63(7), 2003
PMID: 12670888
Bar code screening on combed DNA for large rearrangements of the BRCA1 and BRCA2 genes in French breast cancer families.
Gad S, Klinger M, Caux-Moncoutier V, Pages-Berhouet S, Gauthier-Villars M, Coupier I, Bensimon A, Aurias A, Stoppa-Lyonnet D., J. Med. Genet. 39(11), 2002
PMID: 12414821
DFold: PCR design that minimizes secondary structure and optimizes downstream genotyping applications.
Fredman D, Jobs M, Stromqvist L, Brookes AJ., Hum. Mutat. 24(1), 2004
PMID: 15221783

AUTHOR UNKNOWN, 0

Export

0 Marked Publications

Open Data PUB

Web of Science

View record in Web of Science®

Sources

PMID: 17342152
PubMed | Europe PMC

Search this title in

Google Scholar